Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Mallinckrodt
Harvard Business School
Colorcon
Boehringer Ingelheim

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Palivizumab - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for palivizumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
MedImmune LLCPhase 2/Phase 3
AbbViePhase 3
Regeneron PharmaceuticalsPhase 3

See all palivizumab clinical trials

Recent Litigation for palivizumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
PIECZENIK v. BAYER CORPORATION2010-05-04

See all palivizumab litigation

Pharmacology for palivizumab
Ingredient-typeAntibodies, Monoclonal
Mechanism of ActionFusion Protein Inhibitors

Patent Text Search: US Patents for palivizumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for palivizumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016000049 Germany   Start Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
2015000061 Germany   Start Trial PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
0753 Netherlands   Start Trial PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
2016022 Lithuania   Start Trial PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
2015 00043 Denmark   Start Trial PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Merck
AstraZeneca
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.